美罗培南与头孢哌酮钠舒巴坦治疗老年肺部感染的临床疗效评估

Clinical Efficacy of Meropenem and Cefoperazone Sodium and Sulbactam on Pulmonary Infection in Elderly Patients

目的:探讨美罗培南与头孢哌酮钠舒巴坦治疗老年肺部感染的临床疗效。方法:选取2017年1月～2018年3月我院收治的老年肺部感染患者116例,采用随机字母表法分为观察组与对照组,对照组患者采用头孢哌酮钠舒巴坦治疗,观察组患者采用美罗培南治疗,对比两组患者细菌清除率、临床疗效及不良反应。结果:观察组细菌清除率明显高于对照组,差异有统计学意义(86.26%VS.67.41%,P<0.05);观察组的总有效率明显高于对照组,差异有统计学意义(93.10%VS.77.59%,P<0.05);观察组的不良反应发生率明显低于对照组,差异有统计学意义(3.45%VS.18.97%,P<0.05)。结论:对于老年肺部感染患者,美罗培南的整体临床疗效优于头孢哌酮钠舒巴坦,且安全性较高。

Objective:To explore clinical efficacy of meropenem and cefoperazone sodium and sulbactam in the treatment of elderly patients with pulmonary infection.Methods:A total of 116 cases of elderly patients with pulmonary infection were randomly divided into the observation group and the control group.The cases in observation group were given meropenem treatment,and the cases in control group were given cefoperazone sodium and sulbactam treatment.Bacterial clearance,clinical efficacy and adverse reactions were contrasted between the two groups.Results:Bacterial clearance rate and total effective rate in observation group were both significantly higher than that of control group(86.26%VS.67.41%,and 93.10%VS.77.59%,both P<0.05).Moreover,the incidence of adverse reactions in observation group was obviously reduced,when compared with the control group(3.45%VS.18.97%,P<0.05).Conclusion:Meropenem has better overall effect and higher safety in treatment of elderly patients with pulmonary infection,when compared to cefoperazone sodium and sulbactam.